Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases.

Product information

CAS Number: 1902954-60-2

Molecular Weight: 410.41

Formula: C19H17F3N2O3S

Chemical Name: {[5-(2,4-difluorophenyl)-1-(3-fluorobenzenesulfonyl)-4-methoxy-1H-pyrrol-3-yl]methyl}(methyl)amine

Smiles: CNCC1=CN(C(=C1OC)C1=CC=C(F)C=C1F)S(=O)(=O)C1=CC(F)=CC=C1

InChiKey: OUNXGNDVWVPCOL-UHFFFAOYSA-N

InChi: InChI=1S/C19H17F3N2O3S/c1-23-10-12-11-24(28(25,26)15-5-3-4-13(20)8-15)18(19(12)27-2)16-7-6-14(21)9-17(16)22/h3-9,11,23H,10H2,1-2H3

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

The mechanism of action of Abeprazan is reversibly binding to H+, K+‐ATPase, and, unlike that of PPIs, does not require acidic environment for drug activation.

In Vivo:

DWP14012 inhibited acid secretion in a dose-dependent manner and the inhibition of gastric acid secretion was equal to or greater than that of vonoprazan, a previously approved P-CAB, in various in vivo studies using pylorus-ligated rats, lumen-perfused rat models and heidenhain pouch dog models.

Products are for research use only. Not for human use.